Compare Remitly Global Inc (RELY) vs TG Therapeutics Inc (TGTX) Price & Performance

RELY trades at $24.83, down 5.12% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.93 significantly exceeding expectations of $0.12. Revenue growth is accelerating, reaching $1.64 billion in 2025, with net income turning positive at $67.93 million. A recent partnership with Etsy expands its payment provider reach, signaling business expansion. Analyst consensus is overwhelmingly bullish with a $31.17 price target, representing 25.5% upside from current levels.

The outlook for RELY is positive given its strong revenue trajectory, improving profitability, and strategic partnerships. Key opportunities include continued market share gains in digital remittances and new monetization avenues. Risks involve competitive pressures in fintech, reliance on economic conditions affecting remittance volumes, and potential volatility despite institutional backing. The stock's current pullback may offer a entry point, but investors should weigh execution risks against growth potential.

TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.

The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.